3 241

Cited 0 times in

Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression

Authors
 Jae Hoon Moon  ;  Saet Byol Kang  ;  Jong Suk Park  ;  Byung Wan Lee  ;  Eun Seok Kang  ;  Chul Woo Ahn  ;  Hyun Chul Lee  ;  Bong Soo Cha 
Citation
 Metabolism: Clinical and Experimental, Vol.60(7) : 930-940, 2011 
Journal Title
 Metabolism: Clinical and Experimental 
ISSN
 0026-0495 
Issue Date
2011
Abstract
Low-density lipoprotein receptor-related protein 1 (LRP1) binds to apolipoprotein E and serves as a receptor for remnant lipoproteins in the liver, thus playing an important role in clearing these atherogenic particles. In this study, we investigated the effect of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, on hepatic LRP1 expression. We used HepG2 and Hep3B cells for in vitro study, and Otsuka Long-Evans Tokushima fatty and Sprague-Dawley rats for in vivo study. We used relatively high pharmacologic dose of atorvastatin in this study (in vitro, 0.5 μmol/L in culture media, for 48 hours; in vivo, 20 mg/[kg d], for 6 weeks). Atorvastatin increased LRP1 and low-density lipoprotein (LDL) receptor expression in HepG2 and Hep3B cells and induced hepatic LRP1 and LDL receptor expression in chow diet-fed Sprague-Dawley rats and high-fat diet-fed Otsuka Long-Evans Tokushima fatty rats. Atorvastatin decreased intracellular sterol level and increased the amount of the nuclear form of sterol response element-binding protein-2 (SREBP-2) in both HepG2 and Hep3B cells as well as in two animal models. Treatment of HepG2 cells with LDL increased intracellular sterol level and reduced LRP1, LDL receptor, and SREBP-2. When SREBP-2 in HepG2 cells was knocked down by small interfering RNA, the induction of LRP1 expression by atorvastatin did not take place. In conclusion, up-regulation of hepatic LRP1 might be a novel mechanism by which statin treatment decreases remnant lipoproteins. In addition, SREBP-2 acts as a mediator of atorvastatin-induced up-regulation of hepatic LRP1. Future studies using standard doses of atorvastatin in humans are needed to elucidate clinical relevance of these findings.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93744
Full Text
http://www.sciencedirect.com/science/article/pii/S002604951000301X
DOI
10.1016/j.metabol.2010.08.013
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Medical Research Center (임상의학연구센터)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
강샛별(Kang, Saet Byol)
강은석(Kang, Eun Seok)
문재훈(Moon, Jae Hoon)
박종숙(Park, Jong Suk)
안철우(Ahn, Chul Woo)
이병완(Lee, Byung Wan)
이현철(Lee, Hyun Chul)
차봉수(Cha, Bong Soo)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse